STELARA® IBD - real-world evidence

STELARA^® in Inflammatory Bowel Disease

Real-world evidence confirms STELARA^®’s efficacy seen in clinical trials

Comparative cohort

ENEIDA registry

sustAIN study

In a recent Dutch registry, STELARA^® provides significantly higher effectiveness and lower discontinuation rates compared to vedolizumab at 52 weeks in CD patients with prior anti-TNF failure^[4]

UNADJUSTED PROPORTION OF PATIENTS ACHIEVING CORTICOSTEROID-FREE CLINICAL REMISSION (HBI ≤4) WITH STELARA^® COMPARED TO VEDOLIZUMAB^*^[4]

unadjusted proportion of patients achieving corticosteroid-free clinical remission with STELARA compared to vedolizumab

UNADJUSTED CUMULATIVE DRUGSURVIVAL OF VEDOLIZUMAB-AND STELARA^®-TREATED PATIENTS*^[4]

^*1 patient received Q4W and 1 patient received Q6W dosing.

In the RUN-CD real-world study, STELARA^® shows higher rates of clinical remission at Week 16 in comparison to other biologics†^[5]^[6]

PROPORTION OF PATIENTS ACHIEVING CLINICAL REMISSION WITH STELARA^® VS OTHER BIOLOGICS AT WEEK 16^[5]^[6]

In the RUN-CD real-world study, STELARA^® shows higher rates of health-related QoL improvements at Week 16 in comparison to other biologics‡^[5]

EQ-5D VAS DIFFERENCE BETWEEN BASELINE AND WEEK 16
(INDUCTION PHASE)^§^[5]

CD: Crohn’s disease; HBI: Harvey-Bradshaw Index; q8w: Every 8 weeks; SC: Subcutaneous; TNF: Tumour necrosis factor.

^† Clinical remission (HBI ≤4), and steroid-free remission (HBI ≤4 and no systemic use of steroids or budesonide during the last 8 weeks).
^‡ Other biologics included adalimumab (50.3%), infliximab (37.4%) and vedolizumab (12.3%).
§ Includes mobility, self-care, usual activities, pain/discomfort and anxiety/depression.

Prescribing information | Adverse Events Reporting

References

[1]

Agrawal M, et al. Gastroenterology. 2021; 161(1): 47-65.

[2]

Berg DR, et al. Inflamm Bowel Dis. 2019; 25(12): 1896-1905.

[3]

Loy L, et al. Expert Rev Gastroenterol Hepatol. 2019; 13(6): 547-555.

[4]

Biemans VBC, et al. Aliment Pharmacol Ther. 2020; 52: 123-134.

[5]

Bokemeyer B, et al. Abstract 526 presented at Digestive Disease Week (DDW) 21–23 May 2021. Virtual event.

[6]

Bokemeyer B, et al. DOP47 presented at European Crohn’s and Colitis Organisation (ECCO) 15thCongress, 12–15 February 2020, Vienna, Austria.

[7]

Iborra M, et al. Aliment Pharmacol Ther. 2019; 50: 278-288.

[8]

Iborra M, et al. Aliment Pharmacol Ther. 2020; 50: 1017-1030.

[9]

Chaparro M, et al. Poster presentation P0506 presented at the United European Gastroenterology Week (UEGW), 11-13 October 2020, virtual event.

[10]

Chaparro M, et al. Poster presentation P0507 presented at the United European Gastroenterology Week (UEGW), 11-13 October 2020, virtual event.

[11]

Chaparro M, et al. Poster presentation P263 presented at the European Crohn’s and Colitis Organisation (ECCO), 2-3 & 10-11 July 2021, virtual event.

CP-246633 - January 2021

STELARA® in Inflammatory Bowel Disease

Real-world evidence confirms STELARA®’s efficacy seen in clinical trials

In a recent Dutch registry, STELARA® provides significantly higher effectiveness and lower discontinuation rates compared to vedolizumab at 52 weeks in CD patients with prior anti-TNF failure[4]

UNADJUSTED PROPORTION OF PATIENTS ACHIEVING CORTICOSTEROID-FREE CLINICAL REMISSION (HBI ≤4) WITH STELARA® COMPARED TO VEDOLIZUMAB*[4]

UNADJUSTED CUMULATIVE DRUG SURVIVAL OF VEDOLIZUMAB- AND STELARA®-TREATED PATIENTS*[4]

In the RUN-CD real-world study, STELARA® shows higher rates of clinical remission at Week 16 in comparison to other biologics†[5][6]

PROPORTION OF PATIENTS ACHIEVING CLINICAL REMISSION WITH STELARA® VS OTHER BIOLOGICS AT WEEK 16[5][6]

In the RUN-CD real-world study, STELARA® shows higher rates of health-related QoL improvements at Week 16 in comparison to other biologics‡[5]

EQ-5D VAS DIFFERENCE BETWEEN BASELINE AND WEEK 16 (INDUCTION PHASE)§[5]